Let's talk about it: the questions people ask

Question 1

Is it cheating to use a GLP-1?

Accepted Answer

Not in any medical sense. Cheating means breaking a rule, and there is no rule that weight must come off by effort alone. Weight is shaped by genes and by hunger hormones that push back after weight loss. The Wegovy, Zepbound and Foundayo labels add the medicine to eating less and moving more, rather than replacing them. Whether one suits you, and when, is yours to work out with a clinician.

Question 2

What is a GLP-1, in plain words?

Accepted Answer

GLP-1 is a hormone your own gut makes after you eat. It helps your pancreas release insulin when blood sugar rises, lowers glucagon, slows how fast your stomach empties, and reduces how much people eat. GLP-1 medicines, like semaglutide in Wegovy or tirzepatide in Zepbound, are lab-made molecules that switch on the same receptor and last far longer than the natural hormone.

Question 3

What is food noise, and why does it go quiet?

Accepted Answer

Food noise is an everyday phrase, not a diagnosis. Researchers describe it as persistent, unwanted thoughts about food that feel intrusive. Many people on GLP-1 medicines say it goes quiet, possibly because these medicines act on brain areas tied to appetite and reward. The evidence is early, though. Tools to measure it only date from 2025, and I found no completed randomized trial with food noise as its main outcome.

Question 4

How do Wegovy and Zepbound compare?

Accepted Answer

Both are weekly shots approved for weight in adults, but they differ. Wegovy, semaglutide from Novo Nordisk, also comes as a daily pill and is approved to lower heart attack and stroke risk in people with heart disease. Zepbound, tirzepatide from Eli Lilly, acts on two gut-hormone signals and is approved for sleep apnea with obesity. In an open-label head-to-head trial funded by Lilly, Zepbound averaged more weight loss.

Question 5

Is a pill as good as a shot?

Accepted Answer

The pills work, but neither was tested directly against a shot in the trials behind its approval. The Wegovy pill, oral semaglutide at 25 milligrams, averaged 13.6 percent weight loss at 64 weeks. The Wegovy 2.4 milligram shot averaged 14.9 percent at 68 weeks in its own trial. Foundayo, which is orforglipron, averaged 11.2 percent at its top dose over 72 weeks. Separate trials in different people aren't a direct comparison.

Question 6

How much weight do people really lose?

Accepted Answer

Counting everyone who started, trial averages ran from about 11% to 21% of body weight. At 72 weeks on their top doses, Foundayo, or orforglipron, averaged 11.2% and Zepbound, or tirzepatide, 20.9%. Semaglutide averaged 13.6% as the 25 milligram Wegovy pill at 64 weeks, 14.9% as the 2.4 milligram shot at 68 weeks, and 18.7% as 7.2 milligram Wegovy HD at 72 weeks. Placebo groups lost 2.1% to 3.9%. These were separate trials, not a ranking.

Question 7

What happens if I stop?

Accepted Answer

Usually, much of the weight comes back. In the STEP 1 extension, people who lost 17.3% on semaglutide, sold as Wegovy, had regained about two-thirds of it a year after stopping. In SURMOUNT-4, people who lost 20.9% on tirzepatide, sold as Zepbound, then switched to placebo, regained 14% of body weight within a year. Blood pressure and other markers drift back too. That's biology, not failure.

Question 8

What are the common side effects?

Accepted Answer

Mostly stomach trouble. Nausea, diarrhea, vomiting and constipation lead the list for semaglutide (Wegovy), tirzepatide (Zepbound) and orforglipron (Foundayo). In the label trials, nausea hit 44% on Wegovy 2.4 mg versus 16% on placebo, 28% on Zepbound 15 mg versus 8%, and 35% on Foundayo 17.2 mg versus 10%. These effects are most common while the dose is going up, and they usually ease with time. Headache, tiredness and some hair loss show up too.

Question 9

How much do these medicines cost?

Accepted Answer

It depends on the medicine, the dose and how you pay. As of September 2026, cash prices straight from Novo Nordisk or Lilly ran from $149 to $699 a month. A private plan that covers it, plus a maker's savings card, can bring it to as little as $25. Eligible Medicare members can pay $50 a month through a temporary program that runs through December 2027. List prices are far higher, but most insured people don't pay list.

Question 10

What are the cheapest legitimate ways to pay?

Accepted Answer

Start with the coverage you have. As of September 2026, a covered private plan plus a savings card could get the cost as low as $25 a month. On Medicare, the Bridge is $50 a month if you qualify, through December 2027. Without coverage, the makers' own cash prices went from $149 up to $699 by medicine and dose, and TrumpRx.gov shows the same starting prices. If you're insured, check your copay before paying cash, because it may be lower.

Question 11

Will my insurance cover it?

Accepted Answer

Only your plan can say for sure, but there are patterns. Many job-based plans cover GLP-1s for diabetes but not for weight, and that's usually the employer's choice. Coverage is more common at big employers. When a plan does cover it, it often needs prior authorization first, meaning your prescriber sends proof you meet the plan's rules. One call to the number on your card can settle it.

The facts, from certified documents

How weight and its treatment feel

Life at home, caring for someone

Certified Intelligence™